+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 130 Pages
  • November 2022
  • Region: Global
  • Grand View Research
  • ID: 5450247
Description Jump to:
The global antibody drug conjugates contract manufacturing market size is expected to reach USD 25.79 billion by 2030, registering a CAGR of 12.9% over the forecast period. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

  • By condition, the lymphoma segment is expected to grow at the fastest CAGR over the forecast period
  • A significant number of ADCs under development for lymphoma and collaborations for ADC-related research for lymphoma are supporting the growth of the segment over the forecast period
  • Based on the linker, the cleavable linker segment accounted for the maximum share of the overall revenue in 2022
  • Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based products in the pipeline are the factors responsible for the segment growth
  • Asia Pacific dominated the global industry in 2022 and accounted for the maximum revenue share
  • This is due to the robust improvements in R&D activities in emerging markets and low-cost manufacturing in the region as compared to that of developed countries

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Condition
1.1.2. Linker
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Antibody Drug Conjugates Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of cancer
3.2.1.2. High cost of manufacturing ADC and challenges associated with manufacturing contributing to the demand for contract manufacturing
3.2.1.3. Increasing R&D activities on ADCs
3.2.2. Market restraint analysis
3.2.2.1. Quality issues while outsourcing
3.2.2.2. Limited outsourcing opted by big biopharma Companies
3.3. Antibody Drug Conjugates Contract Manufacturing Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.3.1. Mergers and acquisition
3.3.3.2. Expansions
3.3.3.3. Agreements and collaborations
3.3.3.4. Product and service launches
3.4. Covid-19 Impact and Reformation Strategy
Chapter 4. Antibody Drug Conjugates Contract Manufacturing Market: Condition Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
4.3. Myeloma
4.3.1. Myeloma market estimates and forecast 2018 to 2030 (USD Million)
4.4. Lymphoma
4.4.1. Lymphoma market estimates and forecast 2018 to 2030 (USD Million)
4.5. Breast Cancer
4.5.1. Breast Cancer market estimates and forecast 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Antibody Drug Conjugates Contract Manufacturing Market: Linker Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
5.3. Cleavable linker
5.3.1. Cleavable linker market estimates and forecast 2018 to 2030 (USD Million)
5.4. Non-cleavable linker
5.4.1. Non-cleavable linker market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Antibody Drug Conjugates Contract Manufacturing Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2022 & 2030
6.2. North America
6.2.1. U.S.
6.2.1.1. U.S. market estimates and forecast, 2018 - 2030
6.2.2. Canada
6.2.2.1. Canada market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. U.K.
6.3.1.1. U.K. market estimates and forecast, 2018 - 2030
6.3.2. Germany
6.3.2.1. Germany market estimates and forecast, 2018 - 2030
6.3.3. France
6.3.3.1. France market estimates and forecast, 2018 - 2030
6.3.4. Italy
6.3.4.1. Italy market estimates and forecast, 2018 - 2030
6.3.5. Spain
6.3.5.1. Spain market estimates and forecast, 2018 - 2030
6.3.6. Denmark
6.3.6.1. Denmark market estimates and forecast, 2018 - 2030
6.3.7. Sweden
6.3.7.1. Sweden market estimates and forecast, 2018 - 2030
6.3.8. Norway
6.3.8.1. Norway market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Japan
6.4.1.1. Japan market estimates and forecast, 2018 - 2030
6.4.2. China
6.4.2.1. China market estimates and forecast, 2018 - 2030
6.4.3. India
6.4.3.1. India market estimates and forecast, 2018 - 2030
6.4.4. Australia
6.4.4.1. Australia market estimates and forecast, 2018 - 2030
6.4.5. Thailand
6.4.5.1. Thailand market estimates and forecast, 2018 - 2030
6.4.6. South Korea
6.4.6.1. South Korea market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Brazil market estimates and forecast, 2018 - 2030
6.5.2. Mexico
6.5.2.1. Mexico market estimates and forecast, 2018 - 2030
6.5.3. Argentina
6.5.3.1. Argentina market estimates and forecast, 2018 - 2030
6.6. MEA
6.6.1. South Africa
6.6.1.1. South Africa market estimates and forecast, 2018 - 2030
6.6.2. Saudi Arabia
6.6.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030
6.6.3. UAE
6.6.3.1. UAE market estimates and forecast, 2018 - 2030
6.6.4. Kuwait
6.6.4.1. Kuwait market estimates and forecast, 2018 - 2030
Chapter 7. Competitive Analysis
7.1. Recent Developments & Impact Analysis, By Key Market Participant
7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
7.3. Participant Categorization
Chapter 8. Competitive Landscape
8.1. Company Profiles
8.1.1. Recipharm AB
8.1.1.1. Company overview
8.1.1.2. Financial performance
8.1.1.3. Service benchmarking
8.1.1.4. Strategic initiatives
8.1.2. Samsung Biologics
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Service benchmarking
8.1.2.4. Strategic initiatives
8.1.3. Lonza
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Service benchmarking
8.1.3.4. Strategic initiatives
8.1.4. Piramal Group (Piramal Pharma Solutions)
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Service benchmarking
8.1.4.4. Strategic initiatives
8.1.5. Sterling
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Service benchmarking
8.1.5.4. Strategic initiatives
8.1.6. Sartorius AG
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Service benchmarking
8.1.6.4. Strategic initiatives
8.1.7. Catalent, Inc
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Service benchmarking
8.1.7.4. Strategic initiatives
8.1.8. Wuxi Biologics
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Service benchmarking
8.1.8.4. Strategic initiatives
8.1.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Service benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Merck KGaA
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Service benchmarking
8.1.10.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
List of Figures
Fig 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Antibody drug conjugates contract manufacturing market snapshot (2022)
Fig. 11 Antibody drug conjugates contract manufacturing market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Antibody drug conjugates contract manufacturing market condition outlook: Segment dashboard
Fig. 18 Antibody drug conjugates contract manufacturing market: Condition movement analysis
Fig. 19 Myeloma market (USD Million)
Fig. 20 Lymphoma market (USD Million)
Fig. 21 Breast Cancer market (USD Million)
Fig. 22 Others market (USD Million)
Fig. 23 Antibody drug conjugates contract manufacturing market linker outlook: Segment dashboard
Fig. 24 Antibody drug conjugates contract manufacturing market: Linker movement analysis
Fig. 25 Cleavable Linker market (USD Million)
Fig. 26 Non-Clevable Linker market (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 North America market, 2018 - 2030 (USD Million)
Fig. 30 U.S. market, 2018 - 2030 (USD Million)
Fig. 31 Canada Market, , 2018 -2030 (USD Million)
Fig. 32 Europe Market, , 2018 -2030 (USD Million)
Fig. 33 U.K. Market, , 2018 -2030 (USD Million)
Fig. 34 Germany Market, , 2018 -2030 (USD Million)
Fig. 35 France Market, , 2018 -2030 (USD Million)
Fig. 36 Italy Market, 2018 -2030 (USD Million)
Fig. 37 SpainMarket, 2018 -2030 (USD Million)
Fig. 38 Denmark Market, 2018 -2030 (USD Million)
Fig. 39 SwedenMarket, 2018 -2030 (USD Million)
Fig. 40 Norway Market, By Service, 2018 -2030 (USD Million)
Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 42 China market, 2018 - 2030 (USD Million)
Fig. 43 India market, 2018 - 2030 (USD Million)
Fig. 44 Japan market, 2018 - 2030 (USD Million)
Fig. 45 Australia market, 2018 - 2030 (USD Million)
Fig. 46 Thailand market, 2018 - 2030 (USD Million)
Fig. 47 South Korea market, 2018 - 2030 (USD Million)
Fig. 48 Latin America market, 2018 - 2030 (USD Million)
Fig. 49 Brazil market, 2018 - 2030 (USD Million)
Fig. 50 Mexico market, 2018 - 2030 (USD Million)
Fig. 51 Argentina market, 2018 - 2030 (USD Million)
Fig. 52 MEA market, 2018 - 2030 (USD Million)
Fig. 53 South Africa market, 2018 - 2030 (USD Million)
Fig. 54 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 55 UAE market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Recipharm Ab
  • Samsung Biologics
  • Lonza
  • Piramal Group (Piramal Pharma Solutions)
  • Sterling
  • Sartorius AG
  • Catalent, Inc
  • Wuxi Biologics
  • Abbvie, Inc. (Abbvie Contract Manufacturing)
  • Merck Kgaa

Methodology

Loading
LOADING...

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033 - Product Image

Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033

  • Report
  • 303 Pages
  • Global
From
Antibody Drug Conjugate - Competitive landscape, 2023 - Product Image

Antibody Drug Conjugate - Competitive landscape, 2023

  • Report
  • 650 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.